Fundraising FoxImmunoBiochem
1 known investors
Find your way into ImmunoBiochem
Sign up to see every warm intro you have to ImmunoBiochem
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ImmunoBiochem team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ImmunoBiochem develops degrader-antibody conjugate (DAC) therapeutics that combine antibody targeting with targeted protein degradation for precision immunology and inflammation. Its pipeline targets autoimmune and inflammatory disorders, using computational tools and disease models to design non-cytotoxic payloads.
Investors · 1
Frequently asked questions
- What does ImmunoBiochem do?
- ImmunoBiochem develops degrader-antibody conjugate (DAC) therapeutics that combine antibody targeting with targeted protein degradation for precision immunology and inflammation. Its pipeline targets autoimmune and inflammatory disorders, using computational tools and disease models to design non-cytotoxic payloads.
- Who are ImmunoBiochem's investors?
- ImmunoBiochem's investors include FACIT (Fight Against Cancer Innovation Trust).